Featured
Read our handpicked blogs, curated for you.
|
Your organization runs thousands of AI models across fraud detection, credit scoring, and customer journeys. Yet a…
|
The Enforcement Horizon: August 2, 2026The industry consensus is dominated by the EU AI Act. As of mid-2026, AI systems…
|
The 2026 Industry Consensus: From Policies to EnforcementThe prevailing consensus among global Tier-1 banks is the…
Recent releases
|
Why pharma marketing still flies blind in India
Indian pharma marketing is at a crossroads. Budgets are rising, regulations are tightening, and digital adoption is accelerating. Yet when senior leaders are asked the simplest boardroom question: “…
|
The cost of slow content in pharma marketing and how to amplify it
Every pharma marketer knows the story. A campaign is planned around a new therapy, the slides are drafted, medical-legal-regulatory begins its review, weeks pass, edits keep coming back, and by the…
|
UCPMP 2024 changes pharma marketers must act on
For years, pharma marketing in India carried a reputation for being stuck between outdated field-force practices and patchy digital adoption. That space has shifted. UCPMP 2024 is not just an update…
|
AI-Powered Pharma Market Access: Tier 2 and Tier 3 Strategy
Pharma market access in India has shifted. Growth in metros is plateauing, competition is fierce, and doctors in top cities are over-engaged. The next wave lies in Tier 2 and Tier 3 India, where…
